CompletedPhase 3NCT03068780

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa

Studying Inherited epidermolysis bullosa

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Amryt Research Limited
Principal Investigator: Johannes S Kern, MD PhD
Melbourne Health
Intervention: Oleogel-S10(drug)
Enrollment: 223 target
Eligibility: All sexes
Timeline: 2017 – 2022

Study locations (30)

Phoenix Children's Hospital, Phoenix, Arizona, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Amjad Plastic Research, Miami, Florida, United States
University of Minnesota, Minneapolis, Minnesota, United States
Stony Brook University Hospital, Stony Brook, New York, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
Consutorios Medicos (Instituto de Neumonologia y Dermatologia), Buenos Aires, Argentina
Centro Médico Dra. De Salvo, Buenos Aires, Argentina
Centro de investigaciones Metabolicas, CINME, Buenos Aires, Argentina
Sydney Children's Hospital, Sydney, New South Wales, Australia
Premier Specialists, Sydney, New South Wales, Australia
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03068780 on ClinicalTrials.gov

Other trials for Inherited epidermolysis bullosa

Additional recruiting or active studies for the same condition.

See all trials for Inherited epidermolysis bullosa →

← Back to all trials